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ABSTRACT	Targeted	 therapies	against	disrupter	of	 telomeric	 silencing	1-like	 (DOT1L)	and	bromodomain	 containing	 protein	 4	 (BRD4)	 are	 currently	 being	 evaluated	 in	clinical	 trials.	 However,	 the	 mechanisms	 by	 which	 BRD4	 and	 DOT1L	 regulate	leukemogenic	 transcription	 programs	 remain	 unclear.	 Using	 quantitative	proteomics,	chemoproteomics	and	biochemical	fractionation	we	find	that	native	BRD4	 and	 DOT1L	 exist	 in	 separate	 protein	 complexes.	 Genetic	 disruption	 or	small	molecule	inhibition	of	BRD4	and	DOT1L	shows	marked	synergistic	activity	against	 MLL	 leukemia	 cell	 lines,	 primary	 human	 leukemia	 cells	 and	 mouse	leukemia	models.	Mechanistically,	we	find	a	previously	unrecognized	functional	collaboration	 between	DOT1L	 and	 BRD4	 that	 is	 especially	 important	 at	 highly	transcribed	genes	 in	close	proximity	 to	superenhancers.	DOT1L	via	H3K79me2	facilitates	 the	deposition	of	histone	H4	acetylation,	which	 in	 turn	 regulates	 the	binding	 of	 BRD4	 to	 chromatin.	 These	 data	 provide	 novel	 insights	 into	 the	regulation	 of	 transcription	 and	 specify	 a	molecular	 framework	 for	 therapeutic	intervention	in	this	poor	prognostic	disease.			
	 	
INTRODUCTION	The	 established	 principle	 in	 oncology	 is	 that	 cancer	 is	 a	 disease,	 which	 is	initiated	and	maintained	by	somatic	alterations	in	our	genome.	Recent	advances	in	DNA	sequencing	technologies	have	reaffirmed	this	fact	and	greatly	facilitated	our	molecular	understanding	of	the	genetic	basis	for	various	malignancies1.		The	emerging	challenge	is	to	now	decipher	how	these	genomic	alterations	culminate	in	malignant	transformation	and	how	they	can	be	targeted	for	therapeutic	gain.	A	central	theme	emerging	from	the	cancer	genome	data	is	recurrent	mutations	in	epigenetic	 regulators2.	 In	 fact	 it	 is	 now	 apparent	 that	 mutations	 and/or	translocations	 of	 epigenetic	 regulators	 are	 some	 of	 the	 most	 prevalent	abnormalities	 observed	 in	 hematopoietic	 malignancies3,4.	 The	 realization	 that	epigenetic	regulators	are	widely	implicated	in	the	initiation	and	maintenance	of	cancer	has	fuelled	substantial	interest	in	identifying	targeted	therapies	that	alter	malignant	 transcription	 programs	 and	 offer	 new	 opportunities	 for	 therapeutic	intervention	 in	 these	 malignancies.	 Importantly	 several	 novel	 epigenetic	therapies	 have	 now	 transitioned	 into	 the	 clinical	 arena	 where	 they	 are	 being	assessed	 in	 a	 range	 of	 tumours2,5,6.	 Whilst	 combination	 therapy	 is	 the	cornerstone	 of	 cancer	 management	 and	 is	 also	 the	 future	 for	 emerging	epigenetic	 therapies,	 several	 lines	 of	 evidence	 caution	 against	 an	 empirical	approach	 to	 combination	 epigenetic	 therapy.	Without	 a	 sound	molecular	 basis	additional	benefits	are	often	not	 conferred	by	 these	 combinations	and	 in	 some	cases	 the	 combination	 of	 epigenetic	 therapies	 have	 resulted	 in	 significant	functional	antagonism7-9.	Therefore,	preferred	combinations	should	be	guided	by	a	 thorough	 preclinical	 evaluation	 based	 on	 a	 comprehensive	 understanding	 of	the	molecular	pathogenesis	of	the	disease.			The	mixed	 lineage	 leukemia	 (MLL)	 gene	 codes	 for	 a	histone	methyltransferase	that	plays	an	integral	role	in	normal	embryogenesis	and	the	maintenance	of	both	fetal	 and	 adult	 haematopoiesis10-12.	 	 	 Importantly,	 chromosomal	 translocations	involving	 this	 essential	 epigenetic	 regulator	 accounts	 for	 over	70%	of	 infantile	leukemia	and	up	to	10%	of	adult	leukemia13.	These	MLL	translocated	leukemias	follow	 an	 aggressive	 clinical	 course	 with	 a	 poor	 response	 to	 conventional	
treatment,	 highlighting	 the	 urgent	 need	 for	 better	 therapies	 in	 this	 group	 of	diseases13.	 The	 poor	 prognosis	 conferred	 by	 MLL	 fusion	 protein	 (MLL-FP)	leukemia	 has	 attracted	 significant	 research	 attention	with	 the	 aim	 of	 studying	transcriptional	 dysregulation	 to	 identify	 new	 therapeutic	 opportunities13.	 Thus	far,	several	small	molecules	have	been	developed	to	target	various	components	of	the	transcription	machinery	co-opted	by	MLL-FP14-17.	Many	of	these	targeted	therapies	have	shown	pre-clinical	promise	and	are	currently	being	evaluated	in	clinical	 trials.	Despite	 this	progress,	our	understanding	of	 the	molecular	events	that	 govern	 leukemogenic	 transcription	 programs	 driven	 by	 MLL-FP	 remains	incomplete.			Over	60	different	MLL-translocation	partners	have	been	identified	and	many	of	these	have	been	shown	to	be	members	of	multi-subunit	protein	complexes	that	regulate	 transcription.	 Indeed,	 a	 fundamental	 abnormality	 in	 transcriptional	elongation	appears	to	underpin	the	molecular	pathogenesis	of	MLL	translocated	leukemias18.	Recent	 studies	have	 suggested	 that	 the	 functional	 integrity	of	 two	major	protein	complexes:	the	super-elongation	complex	(SEC)	and	the	disruptor	of	telomeric	silencing	complex	(DOT1Lc),	is	critical	for	malignant	transformation	by	MLL-FP18.	Whilst	 there	 is	 a	 general	 consensus	 that	 the	 various	members	 of	these	 complexes	play	an	 integral	 role	 in	 the	pathogenesis	of	MLL-FP	 leukemia,	there	is	significant	ambiguity	related	to	the	composition	of	these	complexes	and	the	mechanisms	of	transformation.		We	 set	 out	 to	 understand	 if	 BRD4	 and	 DOT1L	 were	 in	 separate	 nuclear	complexes	 and	 if	 they	 function	 in	 a	mutually	 exclusive	manner	 to	 regulate	 the	malignant	 transcription	 programs	 that	 underpin	 MLL-FP	 leukemia.	 Taken	together	 our	 findings	 have	 established	 that	BRD4	 and	DOT1L	mainly	 reside	 in	distinct	 protein	 complexes.	 Whilst	 these	 separate	 complexes	 regulate	 discrete	transcription	programs	in	MLL-FP	leukemia,	there	is	significant	co-operation	and	interdependency	 at	 a	 subset	 of	 genes,	 which	 are	 in	 close	 proximity	 to	superenhancers	and	critical	to	the	molecular	pathogenesis	of	MLL-FP	leukemia.	
At	these	loci	we	find	DOT1L	via	H3K79me2,	facilitates	the	recruitment	of	EP300	to	 acetylate	 Histone	 H4,	 which	 in	 turn	 regulates	 the	 binding	 of	 BRD4	 to	chromatin	 and	 the	 subsequent	 transcriptional	 output	 of	 these	 genes.	 Dual	targeting	 of	 these	 essential	 transcriptional	 regulators	 leads	 to	 a	 profound	suppression	 of	 transcription	 at	 these	 genes,	 which	 are	 important	 to	 the	maintenance	of	MLL-FP	leukemia	thus	providing	a	molecular	rationale	for	future	combination	therapies.		
	
RESULTS	
BRD4	and	DOT1L	are	in	distinct	macromolecular	complexes		Previous	 studies	 have	 established	 that	 the	 functional	 integrity	 of	 the	transcription	 elongation	 complexes	 known	 to	 contain	 BRD4	 or	 DOT1L	 are	critical	to	the	initiation	and	maintenance	of	MLL-FP	leukemia14,19-25.	Nonetheless,	a	significant	unresolved	issue	of	contention	is	whether	BRD4	and	its	associated	positive	 transcription	 elongation	 factor	 b	 complex	 (PTEFb),	 composed	 of	CyclinT1–2	 and	 cyclin-dependent	 kinase	 9	 (CDK9),	 are	 in	 shared	 or	 separate	complexes	 with	 the	 histone	 methyltransferase	 DOT1L.	 Methodological	differences	are	 likely	 to	have	contributed	 to	 this	controversy,	as	virtually	all	of	the	 studies	 performed	 to	 date	 have	 employed	 either	 transient	 or	 stable	expression	of	epitope-tagged	proteins	for	biochemical	and	proteomic	analyses19-25.	We	initially	sought	to	address	this	issue	using	quantitative	mass	spectrometry	and	 specific	 antibodies	 against	 endogenous	 proteins.	 These	 data	 clearly	demonstrate	 that	 BRD4	 associates	with	 CDK9	 as	 part	 of	 the	 PTEFb	 and	 other	members	 of	 the	 previously	 identified	 superelongation	 complex	 (SEC)21,25.	Importantly	 our	 data	 suggest	 that	 BRD4	 and	 PTEFb	 are	 found	 separately	 to	DOT1L	in	various	haematopoietic	cells	that	contain	wild-type	MLL	or	those	that	also	harbour	an	MLL-FP	(Fig.	1a–b,	Supplementary	Fig.	1a).	These	findings	are	further	 supported	 by	 size	 exclusion	 chromatography	 analyses	 of	 the	 native	protein	 complexes	 (Fig.	 1c,	 Supplementary	 Fig.	 1b)	 and	 suggest	 mutual	exclusivity	 of	 complexes	 containing	 BRD4–CDK9	 and	 DOT1L.	 Notably,	 MLLT1	which	 has	 previously	 been	 used	 to	 co-purify	 DOT1L	 and	 CDK923	was	 the	 only	
component	shared	between	the	otherwise	distinct	protein	complexes	containing	BRD4	and	DOT1L.			A	 significant	 advantage	 of	 specific	 small	 molecules	 that	 target	 a	 domain	 of	 a	protein	within	a	macromolecular	complex	is	that	they	can	engage	and	negate	the	functional	activity	of	the	protein	whilst	mostly	preserving	the	native	composition	of	 the	 protein	 complex.	 We	 have	 previously	 used	 this	 beneficial	 property	 to	perform	 chemoproteomics	 to	 identify	 native	 BRD4	 as	 part	 of	 the	 PTEFb–SEC	complex14.	To	extend	these	data	further,	we	fully	characterised	the	specificity	of	the	 DOT1L	 inhibitor,	 SGC094626	 	 (Supplementary	 Fig.	 1c–f,	 Supplementary	
Table	 1),	 and	 functionalised	 it	 so	 that	 it	 could	be	used	as	an	affinity	matrix	 to	purify	DOT1L	and	its	associated	complex	members	(Supplementary	Fig.	2a–b).	These	 interactions	 were	 analysed	 via	 a	 chemoproteomic	 competition	 binding	assay	 (Fig.	 1d,	 Supplementary	 Fig.	 2c).	 Together,	 our	 chemoproteomic	 data	verify	 the	 high	 specificity	 of	 these	 inhibitors	 and	 highlight	 their	 utility	 as	molecular	probes	 to	 interrogate	 the	 function	of	 endogenous	BRD4	and	DOT1L.	These	 data	 also	 confirm	 that	 DOT1L	 and	 BRD4	 exist	 in	 separate	 protein	complexes	albeit	with	some	shared	components	such	as	MLLT1	(Fig.	1e).  
	
Targeting	BRD4	and	DOT1L	results	in	synergy	in	MLL	leukemia	Having	established	that	BRD4	and	DOT1L	are	components	of	two	distinct	protein	complexes,	 we	 next	 sought	 to	 understand	 if	 targeting	 both	 of	 these	transcriptional	 regulators	offered	any	 therapeutic	advantage.	MLL-FP	 leukemia	cells	have	previously	been	shown	to	be	the	most	responsive	molecular	subtype	to	either	DOT1L	or	BET-inhibitor	therapy,	however,	the	kinetics	by	which	BRD4	and	 DOT1L	 inhibition	 exert	 their	 therapeutic	 effects	 in	 MLL-FP	 leukemia	 is	markedly	 different14,15,27.	 Therefore,	 to	 assess	 the	 potential	 benefit	 of	combination	therapy	we	first	established	the	maximum	ineffective	dose	of	I-BET	and	SGC0946	in	various	human	and	mouse	leukemia	cell	lines	(Supplementary	
Fig.	 2d–e	 and	 data	 not	 shown).	 Using	 these	 concentrations,	 we	 were	 able	 to	demonstrate	 that	 combination	 exposure	 to	 I-BET	 and	 SGC0946	 resulted	 in	
marked	 synergistic	 effects	 that	 were	 specific	 to	 MLL-FP	 mouse	 and	 human	leukemia	cell	 lines	(Fig.	 2a–d,	 Supplementary	 Fig.	 2f–h,	 Supplementary	 Fig.	
3a–d).	 Importantly,	 the	 synergistic	 activity	 was	 also	 confirmed	 in	 clonogenic	assays	 with	 several	 primary	 human	 AML	 samples	 containing	 various	 MLL	translocations	(Fig.	2e).			Whilst	in	vivo	delivery	of	the	pre-clinical	BET	bromodomain	inhibitors	has	been	relatively	 straightforward14,	 the	 pharmacokinetic	 properties	 of	 the	 pre-clinical	DOT1L	inhibitor,	EPZ000477	(closely	related	to	SGC0946),	has	posed	significant	challenges	 to	 in	 vivo	 studies	 necessitating	 either	 ex	 vivo	 pretreatment	 of	leukemia	 cells28	 or	 administration	 via	 an	 implantable	 subcutaneous	 osmotic	mini-pump15.	 We	 therefore	 characterized	 the	 pharmacokinetic	 properties	 of	SGC0946	 as	 a	 single	 agent	 or	 in	 combination	 with	 I-BET	 therapy	 in	 vivo	(Supplementary	Fig.	3e–f).	Using	the	optimal	delivery	strategy,	we	investigated	the	 therapeutic	potential	 of	 the	 combination	 in	 an	 aggressive	murine	model	 of	MLL-AF9	 leukemia.	 Consistent	with	our	 in	vitro	 and	ex	vivo	 studies,	 these	data	show	 that	whilst	 sub-therapeutic	 doses	 of	 I-BET	 or	 SGC0946	 offer	 no	 survival	advantage,	 combination	 therapy	 significantly	 prolongs	 survival	 and	 reduces	disease	burden	(Fig.	3a–b,	Supplementary	Fig.	3g).			Previous	studies	have	also	used	genetic	manipulation	of	BRD427,29	or	DOT1L29,30	to	demonstrate	their	individual	role	as	therapeutic	targets	in	MLL-FP	leukemia.	Using	our	previously	validated	inducible	shRNAs	against	BRD431,	 together	with	inducible	 hairpins	 targeting	DOT1L,	we	 replicated	 these	 findings.	Moreover,	 in	agreement	with	our	data	using	 I-BET	and	SGC0946,	we	showed	 that	 combined	knock-down	of	BRD4	and	DOT1L	has	a	more	potent	influence	on	proliferation	in	
vitro	 (Fig.	 3c	and	Supplementary	 Fig.	 4).	To	 further	extend	these	 findings	we	performed	an	in	vivo	competition	assay	to	read	out	the	leukemogenic	potential	of	the	RNAi	expressing	cells.	To	do	this	we	chose	to	use	a	strategy	that	allows	the	reliable	 assessment	of	 the	number	of	RNAi	 expressing	 cells	 at	 all	 times	during	the	 experiment	 including	 the	 time	 when	 the	 mouse	 succumbs	 to	 the	 disease.	Following	the	transplant	of	an	equal	number	of	RNAi	expressing	cells	we	find	at	
multiple	time	points	throughout	the	experiment,	including	the	time	of	death,	that	the	number	of	shRNA	expressing	cells	present	 in	all	 compartments	 (peripheral	blood,	 spleen	 and	 bone	marrow)	 is	 lowest	 in	 the	mice	 transplanted	with	 cells	expressing	 hairpins	 against	 both	 BRD4	 and	 DOT1L	 (Fig.	 3d–f).	 Importantly,	these	data	are	entirely	consistent	with	our	data	using	small	molecules	targeting	DOT1L	 and	 BRD4	 and	 provide	 compelling	 pre-clinical	 evidence	 that	 dual	targeting	of	BRD4	and	DOT1L	provides	significantly	greater	efficacy	 in	MLL-FP	leukemia.				
BRD4	and	DOT1L	co-regulate	a	subset	of	genes	in	MLL	leukemia	In	order	to	understand	the	molecular	basis	for	the	observed	functional	synergy	we	next	sought	to	investigate	the	transcription	programs	regulated	by	BRD4	and	DOT1L.	 The	 transcriptional	 changes	 following	 DOT1L	 or	 BET	 inhibition	 in	MV4;11	 cells	 have	 previously	 been	 studied14,15	 and	 our	 findings	 were	 highly	correlated	with	these	previous	studies	at	identical	time	points	(Supplementary	
Fig.	5a).	In	keeping	with	our	proteomic	and	biochemical	data,	we	find	that	BRD4	and	 DOT1L	 generally	 control	 distinct	 gene	 expression	 programs	 (Fig.	 4a).	Interestingly,	we	find	that	dual	targeting	of	BRD4	and	DOT1L	results	 in	a	more	extensive	and	distinct	alteration	in	gene	expression	that	raised	the	prospect	of	a	functional	interdependency	of	these	two	discrete	transcriptional	complexes	(Fig.	
4a,	Supplementary	Fig.	5b).		To	address	this	possibility	and	better	understand	the	molecular	events	at	chromatin,	we	performed	ChIP-Seq	analyses	following	I-BET	and/or	SGC0946	 treatment	 for	BRD4	binding,	RNA	polymerase-II	 (POL	 II)	occupancy	and	H3K79me2	density,	a	histone	modification	exclusively	deposited	by	DOT1L32.	These	data	identified	three	major	subsets	of	genes	regulated	by	the	DOT1L	and	BRD4	containing	complexes;	those	where	H3K79me2	is	decreased	by	DOT1L	 inhibition	 but	 BRD4	 binding	 is	 either	 absent	 or	 unaffected	with	 I-BET	treatment,	a	set	of	genes	where	BRD4	binding	is	decreased	by	BET	inhibition	but	H3K79me2	 is	 either	 absent	 or	 unaffected	 within	 this	 time	 frame	 by	 SGC0946	treatment	 and	 notably	 a	 third	 subset	 of	 genes	 that	 are	 co-regulated	 by	 both	BRD4	and	DOT1L	(Fig.	4b,	Supplementary	Table	2).	The	genes	co-regulated	by	BRD4	and	DOT1L	inhibition	correlated	highly	with	genes	that	are	downregulated	
by	combination	therapy	in	our	RNA-seq	data	(Fig.	4c).	Importantly,	these	genes	are	also	highly	correlated	with	genes	that	have	been	shown	to	be	directly	bound	by	MLL-FP30	(Fig.	4d)	and	geneGO	analysis	further	highlighted	the	fact	that	these	genes	 are	 also	 critically	 involved	 in	 normal	 and	 malignant	 hematopoiesis	(Supplementary	Fig.	5c).			To	further	study	the	effects	of	BRD4	and/or	DOT1L	inhibition	on	transcriptional	output	 in	 these	 three	 subsets	 of	 genes,	we	 compared	 our	 RNA-Seq	 and	 POL	 II	occupancy	 data	 with	 changes	 in	 BRD4	 displacement	 and/or	 a	 decrease	 in	H3K79me2	(Fig.	 4e,	 Supplementary	Fig.	 5d).	These	data	demonstrate	several	important	findings.	Firstly,	BRD4	displacement	from	chromatin	leads	to	a	more	significant	 alteration	 in	 transcriptional	 output	 than	 a	 decrease	 in	 H3K79me2	(Fig.	4e–f	and	Supplementary	Fig.	5d–e).	As	previously	reported,	we	find	that	H3K79me2	 is	 an	 excellent	 marker	 of	 actively	 transcribed	 genes32	 (Fig.	 5a),	however,	our	data	suggests	that	H3K79me2,	by	itself,	is	not	required	to	maintain	transcriptional	 activity	 at	 the	 vast	majority	 of	 genes	 (Fig.	 4e,	 Supplementary	
Fig.	5d–e).	Importantly,	these	data	also	highlight	the	fact	that	dual	inhibition	of	BRD4	 and	 DOT1L	 results	 in	 a	 dramatic	 suppression	 of	 transcription	 that	 is	especially	notable	at	the	co-regulated	genes	(Fig.	4e–f,	Supplementary	Fig.	5d).				
H3K79me2	regulates	the	binding	of	BRD4	to	chromatin	We	next	wanted	to	understand	the	distinguishing	features	of	the	subset	of	genes	that	 were	 co-regulated	 by	 BRD4	 and	 DOT1L.	 By	 assessing	 POL	 II	 occupancy	across	 the	 coding	 region	 of	 the	 subset	 of	 genes	 that	 are	 regulated	 by	 BRD4	and/or	DOT1L	 inhibition,	we	noted	 that	 the	 co-regulated	genes	were	 the	most	transcriptionally	active	 subset	 (Fig.	 5a).	Highly	 transcribed	genes	 regulated	by	BRD4	have	recently	been	associated	with	superenhancers33,	and	our	findings	are	consistent	with	 this	observation.	Notably	however,	we	can	 further	 refine	 these	previous	observations	by	demonstrating	that	the	genes,	which	are	co-regulated	by	BRD4	and	DOT1L	 in	MLL-FP	 leukemia,	 are	 in	 fact	 the	 subset	of	 genes	most	proximal	to	a	superenhancer	(Fig.	5b).	Whilst	it	has	clearly	been	established	that	
superenhancers	 have	 multiple	 discriminating	 features	 from	 typical	 enhancers,	including	 a	 greater	 occupancy	 of	 transcriptional	 co-activators	 such	 as	 BRD4	(Supplementary	 Fig.	 6a)	 and	 an	 increased	 sensitivity	 to	 BET	 bromodomain	inhibitors33,	the	regulatory	framework	governing	these	intriguing	cis-regulatory	elements	and	their	associated	genes	is	not	fully	understood34.			H3K79me2	is	a	histone	modification	most	commonly	found	throughout	the	gene	body	of	actively	transcribed	genes32.	Interestingly,	we	found	that	H3K79me2	was	also	markedly	enriched	at	transcriptionally	active	superenhancers	compared	to	typical	 enhancers	 (Fig.	 5c–d	 and	 Supplementary	 Fig.	 6b).	 Importantly,	increased	 levels	 of	 H3K79me2	were	 detected	 at	 superenhancers	 regardless	 of	whether	the	superenhancer	was	an	 intragenic	or	 intergenic	regulatory	element	(data	 not	 shown).	 	 Whilst	 BET	 inhibition	 does	 not	 lead	 to	 a	 decrease	 in	H3K79me2	 levels	 (Supplementary	 Fig.	 6c),	 we	 surprisingly	 observed	 that	inhibition	 of	 DOT1L	 results	 in	 a	 marked	 decrease	 in	 the	 binding	 of	 BRD4	 at	superenhancers	 (Fig.	 5e)	 and	 their	 associated	 genes	 in	 human	 MLL–AF4	 and	MLL–AF9	driven	cells	(Supplementary	Fig.	6c,	 e).	Importantly,	dual	 inhibition	results	 in	 a	 near	 complete	 loss	 of	 BRD4	 and	 a	 dramatic	 suppression	 of	transcription	 at	 these	 sites	 (Fig.	 5e	 and	 Supplementary	 Fig.	 6c–d).	 These	intriguing	data	suggest	an	unrecognized	functional	interplay	between	BRD4	and	DOT1L.	 In	 further	 support	of	 this	 contention,	our	genome-wide	data	highlights	the	 specificity	of	 this	 functional	 relationship	by	demonstrating	 that	 although	 I-BET	results	in	BRD4	displacement	from	chromatin	regardless	of	the	presence	or	absence	of	H3K79me2;	DOT1L	 inhibition	only	 results	 in	BRD4	displacement	at	genomic	regions	where	H3K79me2	and	BRD4	binding	are	co-located	(Fig.	5f).			DOT1L	 has	 recently	 been	 shown	 to	 methylate	 non-histone	 proteins35	 and	 we	therefore	wanted	to	understand	whether	the	ability	of	DOT1L	to	regulate	BRD4	binding	at	chromatin	was	via	H3K79	methylation.	To	address	this	question,	we	made	use	of	the	fact	that	SGC0946	has	a	remarkably	long	residence	time26.	This	feature,	coupled	with	the	slow	turnover	of	H3K79me2	(Supplementary	Fig.	1d	and	 Supplementary	 Fig.	 7a–b),	 enabled	 washout	 experiments	 to	 divorce	 the	
potential	 immediate	 effects	 of	 DOT1L	 inhibition,	 with	 unaltered	 H3K79me2,	from	the	effects	mediated	by	decreased	H3K79me2	in	the	absence	of	sustained	DOT1L	inhibition	(Supplementary	Fig.	7).	These	data	clearly	show	that	DOT1L	inhibition,	in	the	absence	of	decreased	H3K79me2,	does	not	alter	BRD4	binding	(Fig.	 5g	 and	Supplementary	 Fig.	 7h).	 In	contrast,	when	H3K79me2	 levels	are	decreased	after	SGC0946	washout,	we	now	observe	a	striking	decrease	in	BRD4	chromatin	occupancy	at	 superenhancers	and	 the	genes	with	overlapping	BRD4	and	 H3K79me2	 (Fig.	 5g	 and	 Supplementary	 Fig.	 7h).	 Taken	 together,	 these	data	 demonstrate	 functional	 reciprocity	 between	 these	 two	 transcriptional	regulators	that	is	mediated	via	H3K79me2.			
H3K79me2	facilitates	histone	H4	acetylation	and	BRD4	binding	To	 understand	 the	 molecular	 mechanism	 that	 underpins	 this	 functional	interdependency,	 we	 concentrated	 our	 efforts	 on	 the	 genes	 co-occupied	 by	H3K79me2	and	BRD4,	whose	expression	was	reduced	by	DOT1L	inhibition.	We	noticed	 that	 the	 majority	 of	 genes	 whose	 expression	 decreased	 following	 a	reduction	 in	 H3K79me2	 also	 had	 an	 accompanying	 loss	 of	 BRD4	 binding	(Supplementary	 Fig.	 8a).	To	decipher	whether	 this	 loss	of	BRD4	binding	was	required	for	the	transcriptional	output	of	these	genes	we	knocked	down	BRD4	in	human	MLL–AF4	and	MLL–AF9	driven	cells,	and	assessed	transcription	at	these	sites.	 These	 data	 demonstrated	 that	 decreased	 BRD4	 levels	 phenocopies	 the	effects	of	DOT1L	 inhibition	at	 these	genes	(Fig.	 6a–b	 and	Supplementary	 Fig.	
8b).	 Importantly,	 these	 data	 also	 provide	 directionality	 for	 the	 sequence	 of	events	as	 the	decrease	 in	BRD4	results	 in	a	change	 in	gene	expression	without	altering	H3K79me2	levels	(Fig.	6c)	suggesting	that	BRD4	binding	is	downstream	of	 H3K79me2	 and	 is	 directly	 responsible	 for	 modulating	 gene	 expression	 at	these	loci.				To	 address	 the	mechanism	 that	 links	H3K79me2	with	 chromatin	 bound	BRD4	we	first	wanted	to	understand	if	BRD4	is	capable	of	directly	binding	H3K79me2.	Using	histone	tail	peptides	that	were	unmethylated	or	mono,	di	or	tri	methylated	
at	 H3K79,	 we	 performed	 immunoprecipitation	 experiments	 from	 nuclear	extracts	that	were	then	assessed	by	quantitative	mass	spectrometry.	These	data	showed	that	BRD4	does	not	directly	bind	H3K79	methylation	(Supplementary	
Fig.	8c).	It	has	previously	been	established	that	BRD4	is	most	avidly	associated	with	chromatin	by	binding	acetylated	lysines	primarily	on	the	tail	of	histone	H4	and	 recent	 data	 demonstrate	 that	 H4K5ac	 is	 the	 modification,	 which	 is	 most	influential	in	regulating	its	avidity	for	chromatin36,37.	An	established	principle	in	chromatin	 biology	 is	 histone	 crosstalk	 whereby	 the	 presence	 or	 absence	 of	 a	histone	modification	may	facilitate	the	deposition	or	removal	of	another	histone	modification38.	We	therefore	assessed	the	possibility	that	H3K79me2,	via	histone	crosstalk,	 influenced	 the	 deposition	 of	 H4K5ac	 at	 these	 loci.	 	 Remarkably	 we	found	that	following	DOT1L	inhibition,	the	reduced	levels	of	H3K79me2	led	to	a	concomitant	 decrease	 in	 H4K5ac.	 These	 changes	 were	 accompanied	 by	decreased	BRD4	binding	and	transcription	of	the	associated	genes	(Fig.	6d	and	
Supplementary	Fig.	8a,	d–e).	Importantly,	this	mode	of	histone	crosstalk	is	also	highly	 specific	 and	 confined	 to	 regions	 of	 the	 genome	 where	 H3K79me2	 and	H4K5ac	overlap	with	BRD4	binding	(Fig.	6e–f	and	Supplementary	Fig.	8a	&	f).		To	 explore	 the	 underlying	 basis	 for	 the	 specific	 regulation	 of	 H4K5ac	 by	H3K79me2,	 we	 asked	 what	 transcription	 factor	 binding	 sites	 are	 most	significantly	enriched	at	the	areas	where	H3K79me2	regulates	H4K5ac.	Notably,	the	 most	 significant	 transcription	 factor	 binding	 site	 enriched	 in	 this	 location	was	CREB1	(Fig.	 7a).	 Importantly,	we	confirmed	 the	 fact	 that	CREB1	 is	 indeed	bound	 at	 a	 number	 of	 genes	 where	 H3K79me2	 influences	 the	 deposition	 of	H4K5ac	and	also	 found	 that	 the	binding	of	CREB1	at	 these	 loci	 is	 regulated	by	DOT1L	mediated	H3K79me2	(Fig.	 7b).	Furthermore,	knock	down	of	CREB1	by	two	 independent	 and	 specific	 shRNAs	 phenocopied	 the	 effects	 of	 DOT1L	 and	BRD4	inhibition	at	these	genes	(Fig.	7c,	Supplementary	Fig.	8g).	Together	these	data	suggest	that	H3K79me2	facilitates	the	DNA	binding	of	transcription	factors	such	as	CREB1	at	genes	 that	are	co-regulated	by	BRD4	and	DOT1L.	CREB1	not	only	 plays	 a	 role	 in	 normal	 and	malignant	 haematopoiesis39	 but	 crucially	 also	
recruits	 CREBBP	 and	 EP300,	 which	 are	 histone	 acetyltransferases	 capable	 of	acetylating	histone	H4K5	and	K840,41.			Consistent	with	 the	possibility	 that	CREB1	recruits	EP300	to	acetylate	H4K5ac,	we	 find	 that	 EP300	 is	 bound	 at	 the	 same	 sites	 as	 CREB1	 and	 moreover	 its	recruitment,	 like	 that	 of	 CREB1,	 is	 dependent	 on	 DOT1L	mediated	H3K79me2	(Fig.	7d).	In	further	support	of	our	data,	we	and	others	find	that	RNAi	mediated	knock	 down	 or	 small	 molecule	 inhibition	 of	 the	 catalytic	 activity	 of	 EP300	 is	highly	 correlated	with	 the	 transcriptional	 effects	 of	 inhibiting	BRD4	 chromatin	occupancy	 (Fig.	 7e)41.	 Taken	 together	 these	 data	 support	 a	 model	 whereby	DOT1L	 methylates	 histone	 H3K79	 leading	 to	 a	 more	 permissive	 chromatin	environment	 for	 the	 binding	 of	 CREB1	 and	 subsequent	 recruitment	 of	 EP300,	which	 in	 turn	 acetylates	 histone	 H4K5	 and	 enables	 the	 binding	 of	 BRD4	 to	potentiate	gene	expression	at	several	critical	MLL-FP	driven	oncogenes	(Fig.	8).			
DISCUSSION	It	 is	 increasingly	 apparent	 that	 a	 fundamental	 imbalance	 in	 the	 epigenetic	regulation	 of	 transcription	 underpins	 the	 molecular	 pathogenesis	 of	 many	cancers	 including	acute	 leukemia.	MLL	 fusion	proteins	are	powerful	oncogenes	and	these	leukemias	have	few	other	genomic	aberrations42.	The	poor	prognosis	conferred	 by	 these	 leukemias	 and	 their	 relatively	 simple	 genetic	 background	have	 provided	 the	 model	 par	 excellence	 for	 understanding	 the	 influence	 of	epigenetic	 regulators	on	malignant	 transcription	programs.	These	 studies	have	yielded	 several	 novel	 epigenetic	 therapies	 which	 are	 now	 being	 investigated	across	a	broad	range	of	malignancies14-17.	Our	clinical	experience	has	highlighted	the	 fact	 that	 monotherapy	 is	 very	 unlikely	 to	 offer	 sustained	 benefit	 in	 the	management	 of	 aggressive	malignancies	 such	 as	MLL-FP	 leukemia.	 It	 has	 also	highlighted	the	pitfalls	of	a	largely	empirical	approach	to	combination	therapies	especially	when	these	involve	the	manipulation	of	context	dependent	epigenetic	regulators8,9.	Therefore	future	combination	therapies	should	be	based	around	a	comprehensive	molecular	rationale.			
	It	 has	 been	 well	 established	 with	 genetic	 experiments	 in	 sophisticated	mouse	models	 that	 DOT1L	 has	 an	 integral	 role	 in	 MLL-FP	 leukemia.30,43,44	 Whilst	H3K79me2	 has	 also	 clearly	 been	 demonstrated	 to	 be	 associated	 with	 active	transcription,	 what	 remains	 uncertain	 is	 whether	 this	 histone	 modification	 is	required	 to	maintain	 the	 transcriptional	 activity	 of	 these	 genes.	 Many	 histone	modifications	 may	 simply	 alter	 the	 local	 chromatin	 environment	 or	 serve	 to	recruit	 specific	 factors	 to	 chromatin	 but	 have	 little	 direct	 effect	 on	transcription.45	Our	data	on	H3K79me2	supports	 the	 fact	 that	H3K79me2	is	an	excellent	marker	 of	 actively	 transcribed	 genes,	 however	 our	 results	 show	 that	DOT1L	 inhibition	 leads	 to	 a	 profound	 decrease	 in	 H3K79me2	 without	 a	significant	change	 in	POL	 II	occupancy	or	 indeed	 transcription	as	measured	by	RNA-Seq	 suggesting	 that	 H3K79me2	 is	 not	 required	 to	 directly	 maintain	transcription	 at	 the	 vast	 majority	 of	 these	 genes.	 It	 has	 recently	 been	demonstrated	 that	 H3K79me2	 helps	 maintain	 an	 open	 chromatin	 state	 by	inhibiting	the	chromatin	localization	of	the	transcriptional	repressors	SIRT1	and	SUV39H128	 and	 consistent	 with	 these	 findings	 our	 results	 suggest	 that	H3K79me2	 provides	 a	 permissive	 chromatin	 state	 for	 the	 recruitment	 of	transcription	 factors	 and	 transcriptional	 co-activators.	 Whilst	 we	 find	 that	H3K79me2	facilitates	the	binding	of	CREB1	and	EP300	which	acetylates	histone	H4	 for	 BRD4	 localization	 it	 is	 also	 possible	 that	 other	 transcription	 factors	and/or	 histone	 acetyltransferases	 could	 be	 recruited	 to	 perform	 analogous	functions.	 Indeed	 a	 recent	 report	 has	 shown	 that	 other	 hematopoietic	transcription	 factors	 in	 association	 with	 EP300	 may	 also	 localize	 BRD4	 to	potentiate	transcription41.			Although	 the	 effects	 of	 BRD4	 and	 DOT1L	 inhibition	 has	 generally	 been	 best	characterized	 in	 the	 MLL-FP	 leukemias,	 there	 is	 emerging	 evidence	 that	therapies	 against	 these	 targets	 may	 play	 a	 role	 in	 other	 molecular	 subsets	 of	acute	leukemia	and	indeed	other	malignancies46-49.	The	differential	sensitivity	to	these	therapies	in	other	cancers	is	presumably	because	of	intrinsic	differences	in	the	molecular	pathogenesis	of	these	diseases	and	the	fact	that	there	are	several	
other	protein	complexes,	which	do	not	contain	DOT1L	or	BRD4,	that	also	nuance	and	 regulate	 malignant	 transcription	 programs	 initiated	 by	 non-MLL-FP	oncogenes50,51.	Nevertheless,	whilst	our	study	has	 focused	on	MLL-FP	 leukemia	we	 do	 not	 exclude	 the	 possibility	 that	 that	 the	mechanism	we	 have	 described	here	may	have	broader	application	in	other	malignancies	and/or	normal	tissues.		These	data	also	have	an	 immediate	clinical	relevance,	as	 therapeutic	responses	to	either	BET	inhibitors52	or	DOT1L	inhibitors53	as	single	agents	have	now	been	reported	in	early	clinical	trials.	As	MLL-FP	leukemias	remain	a	disease	in	urgent	need	for	novel	therapeutic	options,	our	findings	emphasize	the	fact	that	targeting	of	 BRD4	 and	 DOT1L	 in	 combination	 negates	 any	 functional	 compensation	between	 these	 two	discrete,	yet	 interdependent,	 transcription	complexes.	They	provide	a	unifying	mechanism	that	accounts	for	the	exquisite	sensitivity	of	MLL-FP	 leukemia	 to	 DOT1L	 and	 BRD4	 targeted	 therapies	 and	 specify	 a	 molecular	framework	for	future	combination	epigenetic	therapies	in	the	clinical	arena.			
ACCESSION	CODES	RNA-Seq	 and	 ChIP-Seq	 data	 have	 been	 deposited	 in	 the	 Gene	 Expression	Omnibus	database	under	the	accession	code	GSE71780.		
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FIGURE	LEGENDS:	
	
Figure	1:	BRD4	and	DOT1L	are	in	separate	protein	complexes	(a)	 Heat	 map	 summary	 of	 quantitative	 (iTRAQ)	 proteomic	 analysis	 of	immunoprecipitation	 experiments	 (IP).	 Endogenous	 BRD4	 or	 DOT1L	 were	immunoprecipitated	from	HL-60	nuclear	extracts,	enrichment	of	bait	proteins	as	well	as	selected	known	interactors	of	bait	proteins	is	shown	(see	also	Table	S1A).	(b)	Coimmunoprecipitation	of	endogenous	BRD4,	and	MLLT1	in	MOLM-13	cells.	IgG	 was	 used	 as	 a	 control.	 Immunoblot	 (IB)	 analysis	 with	 antibodies	 against	DOT1L.	 (See	 also	 Supplementary	 Data	 Set	 1).	 (c)	 Size	 exclusion	chromatography	 performed	 on	 HEL	 nuclear	 extracts	 followed	 by	 immunoblot	analysis	of	BRD4,	DOT1L,	 and	CDK9.	 (d)	Chemoproteomic	 competition	binding	assay.	 Mass	 spectrometry	 analysis	 of	 eluates	 from	 HL-60	 nuclear	 extracts	incubated	 with	 the	 SGC0946	 matrix	 in	 the	 presence	 of	 DMSO	 or	 increasing	concentrations	 of	 SGC0946.	 (e)	 Scatterplot	 of	 chemoproteomic	 enrichment	 of	proteins	captured	via	a	SGC0946	matrix	or	a	I-BET	matrix	and	competition	with	the	respective	free	compound.			
Figure	2:	Inhibition	of	BRD4	and	DOT1L	leads	to	synergistic	efficacy	against	
MLL-FP	leukemia	cell	lines	and	primary	patient	cells	
	(a)	Proliferation	assay	performed	with	human	MV4;11	cells	treated	with	DMSO,	I-BET,	 SGC0946	 or	 both.	 Mean,	 error	 bars,	 s.d.	 (n	 =	 3	 cell	 culture	 replicates),	representative	 graph	 from	 experiments	 done	 on	 3	 separate	 occasions.	 (b)	Proliferation	assay	of	mouse	MLL–AF9	 leukemia	cells.	Low	dose	and	high	dose	respectively	were	 defined	 in	 Supplementary	 Figure	 2.	 For	 I-BET,	 LD	 =	 100nM	and	HD	=	500nM.	For	SGC0946,	LD	=	1µM	and	HD	=	5µM.	Mean,	error	bars,	s.d.	(n=3	cell	culture	replicates),	 representative	graph	 from	experiments	done	on	3	separate	 occasions.	 (c)	 Proliferation	 assay	with	 K562	 driven	 by	 BCR–ABL	 and	(d)	KG-1	cells.	Mean,	error	bars,	s.d.	(n	=	3	cell	culture	replicates),	representative	graph	 from	 experiments	 done	 on	 3	 separate	 occasions.	 (e)	 Clonogenic	 assays.	primary	 human	 MLL-FP	 AML	 cells	 were	 plated	 in	 the	 presence	 of	 vehicle	(DMSO),	 I-BET	(LD),	SGC0946	(LD)	or	combination	of	 I-BET	(LD)	and	SGC0946	
(LD).	Mean	(n	=	2	cell	culture	replicates).	
	
Figure	3:	Inhibition	of	BRD4	and	DOT1L	by	small	molecule	and	shRNA	leads	
to	synergistic	efficacy	against	MLL-FP	leukemia	in	vivo	(a)	Kaplan–Meier	curve	of	vehicle	and	drug	treated	C57BL/6	mice	transplanted	with	2	×	106	MLL–AF9	leukemic	cells.	Black	arrows	represent	treatment	with	I-BET	at	a	 low	dose	of	10mg/kg/day	via	 IP	 injections	and	shaded	orange	 region	represents	treatment	with	SGC0946	at	6mg/kg/h	via	continuous	osmotic	pump	delivery,	 n=5	 mice	 per	 group.	 P	 values	 are	 calculated	 using	 log-rank	 test.	 (b)	Spleen	weights	 of	 the	mice	 from	 the	 various	 treatment	 cohorts.	 n=5	mice	 per	group.	 The	 upper	 limit,	 center	 and	 lower	 limit	 of	 boxplots	 denote	 the	 upper	quartile,	median	and	lower	quartile	of	the	data,	respectively.	Whiskers	extend	to	maximum	 and	 minimum	 values.	 P-value	 by	 two-tailed	 Student’s	 t	 test.	 (c)	Competition	 assay	 of	 inducible	 shScramble	 with	 shBRD4	 and/or	 shDOT1L	 in	mouse	MLL–AF9	cells	 treated	with	doxycycline	 for	8	days.	dsRED	positive	cells	were	normalized	to	day	1	post	doxycycline	exposure.	Mean,	error	bars,	s.d.	(n=3	cell	 culture	 replicates),	 representative	 graph	 from	 experiments	 done	 on	 2	separate	occasions.	(d-f)	Percentage	of	shRNA+/dsRED+	cells	post	transplant	of	leukemic	 cells.	 The	 upper	 limit,	 center	 and	 lower	 limit	 of	 boxplots	 denote	 the	upper	 quartile,	 median	 and	 lower	 quartile	 of	 the	 data,	 respectively.	 Whiskers	extend	 to	maximum	and	minimum	values.	Percentage	of	shRNA+/dsRED+	cells	in	the	(d)	peripheral	blood	at	day	18,	(e)	spleen	at	endpoint	and	(f)	bone	marrow	at	endpoint.	n=5	mice	per	group.		
Figure	 4:	 A	 subset	 of	 genes	 is	 responsive	 to	 both	 BRD4	 and	 DOT1L	
inhibition.	(a)	 RNA-Seq	Principal	 component	 analysis	 of	MV4;11	 cells	 treated	with	 I-BET,	SGC0946,	 or	 a	 combination	 of	 I-BET	 and	 SGC0946,	 and	 vehicle	 control	 in	experiments	 done	 on	 2	 separate	 occasions.	 (b)	 ChIP-Seq	 for	 H3K79me2	 and	BRD4	after	treatment	with	I-BET	or	SGC0946.	Top,	venn	diagram	of	the	number	of	 genes	 in	 each	 of	 the	 three	 categories	 of	 BRD4	 and	 DOT1L	 regulated	 genes.	Bottom,	ChIP-Seq	profiles	of	an	exemplar	gene	from	each	category.	(c)	Gene	set	enrichment	analysis	(GSEA)	of	the	down-regulated	genes	following	combination	
treatment	of	MV4;11	cells	with	the	co-regulated	subset	of	genes.	(d)	GSEA	of	the	genes	 down-regulated	 by	 combination	 treatment	 with	 previously	 published	MLL–AF9	 fusion	 target	 genes30.	 (e)	 Log-fold	 changes	 in	 BRD4	 binding	 (BRD4	LFC)	and	H3K79me2	levels	(H3K79me2	LFC)	in	genes	from	ChIP-Seq	are	plotted	against	 the	change	 in	POL	 II	 (POL	 II	LFC)	binding	 following	 I-BET,	SGC0946	or	combination	 treatment.	The	numbers	of	genes	 in	each	quadrant	are	 shown.	 (f)	Waterfall	 plot	 demonstrating	 the	 change	 in	 POL	 II	 (POL	 II	 LFC)	 binding	throughout	the	gene	body	of	the	co-regulated	genes,	ranked	by	increasing	POL	II	LFC,	following	I-BET,	SGC0946	or	combination	treatment.			
Figure	5:	DOT1L	regulates	BRD4	binding	at	superenhancers	via	H3K79me2	(a)	Median	POL	II	coverage	(RPKM)	across	the	four	subsets	of	BRD4	and	DOT1L	regulated	genes	in	vehicle	treated	cells	from	ChIP-Seq.	Regions	5kb	upstream	of	the	TSS	(transcription	start	site)	to	5kb	downstream	of	the	TES	(transcriptional	end	site)	are	in	250bp	bins.	The	gene	body	is	scaled	to	bins	consisting	of	1%	of	gene	 length.	 (b)	 Distribution	 of	 distance	 to	 the	 nearest	 superenhancer	 for	 the	four	 subsets	 of	BRD4	and	DOT1L	 regulated	 genes.	 (c)	The	median	 coverage	of	H3K79me2	(RPKM)	from	ChIP-Seq	across	superenhancers	and	typical	enhancers	with	 5kb	 upstream	 and	 downstream	 in	 untreated	 cells.	 (d)	 4sU	 RNA-Seq	coverage	in	enhancers	with	and	without	H3K79me2.	The	upper	limit,	center	and	lower	limit	of	boxplots	denote	the	upper	quartile,	median	and	lower	quartile	of	the	 data,	 respectively.	Whiskers	 extend	 to	 1.5	×	 interquartile	 range	 above	 and	below	the	upper	and	lower	quartiles,	respectively.	(e)	Median	coverage	(RPKM)	of	 BRD4	 binding	 from	 ChIP-Seq	 across	 superenhancers	 and	 typical	 enhancers	with	5kb	upstream	and	downstream	 following	 I-BET,	SGC0946	or	 combination	treatment.	 (f)	 BRD4	 binding	 in	 genomic	 regions	 where	 only	 BRD4	 is	 present	compared	 to	 regions	 where	 BRD4	 and	 H3K79me2	 occur	 together.	 The	 upper	limit,	center	and	lower	 limit	of	boxplots	denote	the	upper	quartile,	median	and	lower	 quartile	 of	 the	 data,	 respectively.	Whiskers	 extend	 to	 1.5	×	 interquartile	range	above	and	below	the	upper	and	lower	quartiles,	respectively.	(g)	Median	BRD4	 coverage	 (RPKM)	 at	 superenhancers	with	H3K79me2,	 following	8	hours	SGC0946	treatment	or	72	hours	post	SGC0946	washout.	
	
Figure	6:	H3K79me2	regulates	BRD4	binding	via	H4	acetylation	(a)	GSEA	of	 the	genes	down-regulated	by	SGC0946	with	genes	down-regulated	by	BRD4	shRNA	knock-down	in	MV4;11	cells.	(b)	shRNA	mediated	knockdown	of	BRD4	in	MOLM-13	cells.	Bar	graphs	represent	the	relative	mRNA	levels	 .	Mean,	error	bars,	s.d.	(n	=	3	experiments	done	on	separate	occasions)	*P	<	0.05,	**P	<	0.01	by	 two-tailed	 student’s	 t	 test.	 (c)	 qPCR	analysis	 of	H3K79me2	ChIP	using	primers	 against	 CDK6,	 MTHFD2	 and	 ATF4.	 Mean,	 error	 bars,	 s.d.	 (n=3	experiments	 done	 on	 separate	 occasions).	 (d)	 ChIP-Seq	 profile	 of	 CDK6	with	SGC0946	treatment	in	MV4;11	cells.	(e)	Log-fold	changes	in	the	levels	of	H4K5ac	upon	 SGC0946	 treatment	 in	 genomic	 regions	 where	 only	 BRD4	 is	 present	compared	 to	 regions	 where	 BRD4	 and	 H3K79me2	 occur	 together.	 The	 upper	limit,	center	and	lower	 limit	of	boxplots	denote	the	upper	quartile,	median	and	lower	 quartile	 of	 the	 data,	 respectively.	Whiskers	 extend	 to	 1.5	×	 interquartile	range	above	and	below	the	upper	and	lower	quartiles,	respectively.	(f)	Metagene	profiles	of	BRD4	and	H3K79me2	normalised	read	counts	centred	on	regions	with	H4K5	acetylation.			
Figure	 7:	 H3K79me2	 regulates	 BRD4	 binding	 via	 EP300	 mediated	 H4	
acetylation	(a)	 MEME	 Motif	 analysis.	 Left,	 Enrichment	 of	 the	 CREB1	 motif	 in	 positive	genomic	 regions	 with	 both	 BRD4	 and	 H3K79me2	 where	 BRD4	 binding	 and	H4K5ac	levels	are	lost	following	SGC0946	treatment.	Negative	regions	represent	those	 where	 H4K5ac	 levels	 are	 unaltered.	 Right,	 Sequence	 logo	 of	 the	 CREB1	motif.	(b)	qPCR	of	CREB1	ChIP	using	primers	against	CDK6,	MTHFD2	and	ATF4	and	Negative	 control	 region	 (neg)	 in	MV4;11	 cells.	Mean,	 error	 bars,	 s.d.	 (n=3	experiments	done	on	separate	occasions).	(c)	qRT-PCR	of	CREB1	knockdown	by	two	 independent	 shRNAs	 using	 primers	 against	 CDK6,	MTHFD2	 and	 ATF4	 in	MV4;11	cells.	Bar	graphs	represent	 the	relative	mRNA	levels.	Mean,	error	bars,	s.d.	(n	=	3	experiments	done	on	separate	occasions).		(d)	qPCR	analysis	of	EP300	ChIP	using	primers	against	CDK6,	MTHFD2,	ATF4	and	B2M.	Mean,	error	bars,	s.d.	(n	 =	 3	 experiments	 done	 on	 separate	 occasions).	 (e)	 GSEA	 of	 genes	 down-
regulated	by	shRNA-mediated	BRD4	knock	down	in	mouse	MLL–AF9	cells	with	genes	 previously	 found	 to	 be	 down-regulated	 by	 Ep300	 knock	 down	 or	 small	molecule	inhibition	in	the	same	leukemia	model31.	
	
Figure	 8:	 Schematic	 model	 for	 the	 functional	 interdependency	 of	 DOT1L	
and	BRD4	in	MLL-Leukemia		H3K79	 is	methylated	by	DOT1L,	which	 results	 in	 a	more	 open	 and	permissive	chromatin	environment	 for	 the	binding	of	 transcription	 factors	such	as	CREB1.	This	in	turn	results	in	the	recruitment	of	EP300,	which	catalyses	the	acetylation	H4K5.	BRD4	and	its	associated	protein	complex	subsequently	binds	to	H4K5ac	to	facilitate	the	transcription	of	target	genes.		 	
ONLINE	METHODS	
Generation	 of	 immortalised	 primary	 murine	 haematopoietic	 progenitor	
cell	lines		Initial	 generation	 of	 an	 immortalised	 parental	 cell	 line	 was	 achieved	 through	magnetic	 bead	 selection	 (Miltenyi	 Biotec)	 of	 c-kit	 positive	 cells,	 obtained	 from	whole	 bone	 marrow	 of	 male	 and	 female	 C57BL/6	 mice,	 and	 subsequent	retroviral	transduction	with	a	MSCV-MLL-AF9-IRES-YFP	construct.			
Cell	culture	Primary	murine	haematopoietic	progenitors	and	derived	cell	 lines	were	grown	in	RPMI-1640	supplemented	with	murine	IL-3	(10	ng/mL),	20%	fetal	calf	serum,	penicillin	 (100	 units/mL),	 streptomycin	 (100	 µg/mL),	 amphotericin	 B	(250ng/mL)	 and	 gentamycin	 (50	 µg/mL).	 Primary	 human	 leukemia	 cells	were	grown	in	the	presence	of	IL3	(10	ng/mL),	IL6	(10	ng/mL)	and	SCF	(50	ng/mL).	Cells	were	incubated	at	37°C	and	5%	CO2.	MV4-11,	MOLM-13,	KG-1,	NB-4,	HL-60	and	 SKM-1	 cells	were	 grown	 in	 RPMI-1640	 supplemented	with	 20%	 fetal	 calf	serum,	 glutamax,	 penicillin	 (100units/mL),	 and	 streptomycin	 (100µg/mL).	Trypan	Blue	staining	was	performed	 for	all	 cell	 counting.	4%	Trypan	Blue	was	added	to	a	sample	of	cell	culture	media	at	1:1	ratio,	and	cell	count	calculated	by	BioRad	automated	cell	counter.	All	cell	lines	were	authenticated	by	short	tandem	repeat	(STR)	profiling	using	the	AmpFISTR® dentifier®	kit,	applied	biosystems,	and	tested	for	mycoplasma	contamination	every	two	months.		
	
Cell	proliferation	assays	Cells	were	 seeded	 at	 5	×	 104	cells/mL	 in	 duplicates	 and	 treated	with	DMSO,	 I-BET,	SGC0946	or	both	and	counted	daily	for	4–6	days	using	a	BioRad	automated	cell	counter.		
	
Clonogenic	assays	in	methylcellulose		
Clonogenic	 potential	 was	 assessed	 through	 colony	 growth	 of	 human	 patient	samples	 plated	 in	 cytokine-supplemented	 methylcellulose	 (Methocult	 M3434,	Stemcell	Technologies).	Human	patient	MLL	samples	were	plated	in	duplicate	at	a	cell	dose	of	2	×	102	per	plate	in	the	presence	of	vehicle	(0.1%	DMSO)	or	drug	(750nM	I-BET151,	1µM	SGC0946	or	both).	Cells	were	incubated	at	37°C	and	5%	CO2	for	7	to	10	days	at	which	time	colonies	were	counted.			
Flow	cytometric	analyses	Cell	 apoptosis	 was	 assessed	 using	 APC	 conjugated	 Annexin	 V	 (550475,	 BD	Biosciences)	 and	 propidium	 iodide	 (PI)	 (P4864,	 Sigma-Aldrich)	 staining	according	 to	 manufacturer’s	 instructions.	 Induction	 of	 apoptosis	 in	 human	leukemia	 cell	 lines	 was	 determined	 following	 treatment	 with	 either	 vehicle	(DMSO)	or	500nM	I-BET151	 for	24	 to	48	hours	 in	 liquid	culture.	For	cell	 cycle	analysis,	 cells	 were	 fixed	 overnight	 at	 –20°C	 in	 70%	 EtOH/PBS.	 Prior	 to	 flow	cytometry	 analysis,	 cells	 were	 incubated	 at	 37°C	 for	 30	 mins	 in	 PI	 solution	(0.02mg/mL	 PI,	 0.05%	 v/v	 Triton-X	 in	 PBS,	 supplemented	 with	 DNase-free	RNAse	 A	 (19101,	 Qiagen)).	 Flow	 cytometry	 analyses	 were	 performed	 on	 a	LSRFortessa	 X-20	 flow	 cytometer	 (BD	 Biosciences)	 and	 all	 data	 analysed	with	FlowJo	 software	 (Tree	Star).	 Cell	 sorting	was	performed	on	a	FACSAria	Fusion	flow	sorter	(BD	Biosciences).			
Size	exclusion	chromatography	Cell	lysates	were	separated	on	a	superose-6	column	and	fractions	collected	were	analysed	by	western	blot	for	the	presence	of	proteins	of	interest.			
Chemoproteomics	HL-60	nuclear	extracts	have	been	prepared,	and	immunoprecipitations	of	BRD4	and	 DOT1L	 performed,	 as	 previously	 described14.	 Briefly,	 antibodies	 (anti-BRD414;	anti-DOT1L,	Novus	Biologicals	#NB100-40845)	and	a	control	rabbit	IgG	(Sigma	 #15006)	 were	 covalently	 coupled	 to	 100ul	 AminoLink	 resin	 (Thermo	
Fisher	Scientific	#20501).	The	immobilized	antibodies	were	incubated	with	HL-60	nuclear	extracts	for	3	hours,	rotating	at	4°C.	Beads	were	washed	and	protein	was	recovered	for	LC-MS/MS	analysis.		Affinity	matrices	were	 generated	 and	 affinity	 profiling	 assays	were	 performed	with	HL-60	nuclear	 extracts	 as	 described	previously14.	 Beads	were	derivatized	with	20	µM	GSK2691981,	an	analogue	of	GSK1210151,	or	1	mM	GSK3338813A	(see	Supplementary	Notes),	an	analogue	of	SGC0946.	LC-MS/MS	 analysis:	 Sample	 preparation,	 labeling	 with	 isobaric	 mass	 tags,	peptide	 fractionation,	 and	 mass	 spectrometric	 analyses	 were	 performed	essentially	as	described54,55.	All	experiments	 (except	BRD4	IP)	were	performed	using	the	TMT™	(Thermo-Fisher	Scientific)	multiplex	option	to	allow	comparison	of	up	to	10	conditions	in	one	analysis56.	Peptide	and	protein	identification:	Mascot	2.4	(Matrix	Science,	Boston,	MA)	was	used	for	protein	identification	by	using	a	10	parts	per	million	mass	tolerance	for	peptide	 precursors	 and	 20	 mD	 (HCD)	 mass	 tolerance	 for	 fragment	 ions.	Carbamidomethylation	 of	 cysteine	 residues	 and	 TMT	 modification	 of	 lysine	residues	 were	 set	 as	 fixed	 modifications	 and	 methionine	 oxidation,	 and	 N-terminal	acetylation	of	proteins	and	TMT	modification	of	peptide	N-termini	were	set	 as	 variable	 modifications.	 The	 search	 database	 consisted	 of	 a	 customized	version	of	the	International	Protein	Index	protein	sequence	database	combined	with	a	decoy	version	of	this	database	created	by	using	a	script	supplied	by	Matrix	Science.	Unless	stated	otherwise,	we	accepted	protein	identifications	as	follows:	(i)	For	single-spectrum	to	sequence	assignments,	we	required	this	assignment	to	be	the	best	match	and	a	minimum	Mascot	score	of	31	and	a	10×	difference	of	this	assignment	 over	 the	 next	 best	 assignment.	 Based	 on	 these	 criteria,	 the	 decoy	search	 results	 indicated	 <1%	 false	 discovery	 rate	 (FDR).	 (ii)	 For	 multiple	spectrum	 to	 sequence	 assignments	 and	 using	 the	 same	 parameters,	 the	 decoy	search	results	 indicate	<0.1%	FDR.	All	 identified	proteins	were	quantified;	FDR	for	quantified	proteins	was	<1%.		Peptide	and	protein	quantification:	Reporter	ion	intensities	were	read	from	raw	data	and	multiplied	with	ion	accumulation	times	(the	unit	is	milliseconds)	so	as	to	yield	a	measure	proportional	to	the	number	of	ions;	this	measure	is	referred	
to	 as	 ion	 area57.	 Spectra	 matching	 to	 peptides	 were	 filtered	 according	 to	 the	following	criteria:	mascot	 ion	score	>15,	 signal-to-background	of	 the	precursor	ion	 >4,	 and	 signal-to-interference	 >0.558.	 Fold-changes	 were	 corrected	 for	isotope	 purity	 as	 described	 and	 adjusted	 for	 interference	 caused	 by	 co-eluting	nearly	 isobaric	 peaks	 as	 estimated	 by	 the	 signal-to-interference	 measure	 59.	Protein	quantification	was	derived	from	individual	spectra	matching	to	distinct	peptides	 by	 using	 a	 sum-based	 bootstrap	 algorithm;	 95%	 confidence	 intervals	were	calculated	for	all	protein	fold-changes	that	were	quantified	with	more	than	three	spectra	57.	For	visualization	only	proteins	with	≥2	peptides	and	≥3	spectra	were	considered	in	heatmap	and	scatter	plot	representation	(Figure	1a	and	e).		
Co-immunoprecipitation	4	×	107	MV411	or	MOLM-13	cells	were	harvested.	Cells	were	washed	in	ice	cold	PBS	 and	 centrifuged	 at	 400g	 for	 5	 minutes,	 4C	 (×2)	 and	 lysed	 in	 600µL	 of	Modified	HEPES	Lysis	Buffer,	(appendix	II)	with	(1×)	Protease	inhibitor	cocktail	solution	(Roche)	for	2	minutes.	Cell	debris	was	precipitated	by	centrifugation	at	maximum	 speed	 (15,000rpm)	 for	 10	 min.	 A	 100µL	 sample	 was	 collected	 for	Western	Blot	input	control,	before	being	diluted	with	500µL	of	50M	Tris	Buffer.	1mL	of	supernatant	was	aliquoted	and	split	between	two	eppendorf	tubes.	40µL	Magnetic	Dynabeads®;M-280	Strepdavidin	(Invitrogen)	were	washed	in	HEPES	lysis	wash	buffer	(3×)	and	then	incubated	with	lysates	for	3	hours	at	4	degrees	on	 spinning	 rotator	 (SB3,	 Stuart).	 After	 incubation	 magnetic	 beads	 were	precipitated	 using	 a	 Dyna	 Mag	 2	 magnet	 (Life	 technologies).	 Samples	 were	washed	in	modified	HEPES	wash	lysis	buffer	(2×)	utilizing	Dyna	Mag	2	for	bead	separation;	 final	 pellet	was	 re-suspended	 in	 50ul	 of	wash	 lysis	 buffer.	 10µL	 of	SDS	sample	buffer	was	added	to	bead	bound	protein	‘sample’	solution,	and	20µL	to	input	sample,	and	incubated	at	95	degrees	for	5	minutes.			
Immunoblotting	
Whole	 cell	 lysates	 were	 mixed	 with	 Laemmli	 buffer,	 separated	 via	 SDS-PAGE,	transferred	to	PVDF	membranes	(Millipore).	Membranes	were	then	sequentially	incubated	 with	 primary	 antibodies	 (see	 antibodies)	 and	 secondary	 antibodies	conjugated	 with	 horseradish	 peroxidase	 (Invitrogen).	 Membranes	 were	 then	incubated	with	ECL	(GE	Healthcare)	and	proteins	detected	by	exposure	to	x-ray	film.			
RNAi	studies			shRNAs	were	cloned	into	a	tet-on	inducible	vector	backbone,	TtRMPVIR	(27995,	addgene).	For	competitive	proliferation	assays,	transduced	cells	were	sorted	for	shRNA-containing	 (Venus+/YFP+	 or	 BFP+/YFP+)	 and	 non	 shRNA-containing	(YFP+	only)	populations	and	recombined	at	a	1:1	ratio.	Following	this,	cells	were	cultured	with	1mg/mL	doxycycline	to	induce	shRNA	expression.	The	proportion	of	 shRNA-expressing	 (dsRED+/	 Venus+/YFP+)	 cells	 were	 determined	 by	 flow	cytometric	 analysis	 and	 followed	 over	 time.	 Knockdown	 efficiency	 of	 shRNA-expressing	and	non	shRNA-containing	cells	was	assessed	following	72	hours	of	doxycycline	 exposure	 by	 qRT-PCR	 and	 immunoblotting.	 Sequence	 of	 shRNA	 in	
Supplementary	Notes.	
	
qRT-PCR		mRNA	 was	 prepared	 using	 the	 Qiagnen	 RNeasy	 kit	 and	 cDNA	 synthesis	 was	performed	using	SuperScript	VILO	kit	(Life	Technologies)	as	per	manufacturers’	instructions.	 Quantitative	 PCR	 analysis	 was	 undertaken	 on	 an	 Applied	Biosystems	 StepOnePlus	 System	 with	 SYBR	 green	 reagents.	 For	 analysis	 of	murine	 cell	 line	 samples,	 expression	 levels	 were	 determined	 using	 the	 ΔCT	method	and	normalised	 to	beta-2-microglobulin	and/or	GAPDH.	Assessment	of	expression	 changes	 associated	 with	 I-BET151	 treatment	 occurred	 at	 6	 hours	following	 treatment	 with	 500nM	 I-BET151	 and/or	 SGC0946	 for	 72–96hrs.	Sequence	of	primers	in	Supplementary	Notes.		
SGC0946	Washout		Cells	were	cultured	 for	6,	8	or	10hrs	with	SGC0946,	after	which	the	compound	was	washed	out	and	cells	replaced	with	fresh	media.	Cells	were	then	cultured	up	to	72hrs	and	harvested.	Short-term	treatment	was	performed	on	the	same	batch	of	cells	just	prior	to	harvesting.			
Antibodies	The	 following	 antibodies	 were	 used	 in	 ChIP	 assays:	 anti-BRD4	 (E2A7X,	 cell	signalling),	 anti-H3K27ac	 (ab4729,	 abcam),	 Anti-H3K79me2	 (ab3594,	 abcam),	anti-RNA	POL	II	(CTD4H8,	Millipore).	Immunobloting	assays:	anti-BRD4	(A301-985A,	 Bethyl	 Labs	 and	 ab128874,	 abcam)	 anti-HSP60	 (sc-13966,	 Santa	 Cruz	Biotechnology),	 anti-H3K79me2	 (ab3594,	 abcam),	 anti-MYC	 (9402S,	 Cell	signalling	technologies),	anti-CDK9	(A303-492A,	Bethyl	Labs),	anti-LEO1	(A300-174A,	 Bethyl	 Labs),	 anti-MLLT1	 (A302-267A,	 Bethyl	 Labs),	 anti-DOT1L	(ab72454,	 abcam),	 Anti-IgG	 rabbit	 (Santa	 Cruz	 Biotechnology),	 anti-P300	(ab14984,	 abcam),	 anti-H4K5ac	 (ab51997,	 abcam),	 anti-CREB1	 (48H2,	 cell	signalling).	Validation	is	provided	on	the	manufacturer’s	website.		
Pharmacokinetic	optimization	of	SGC0946	delivery	The	systemic	exposure	of	SGC0946	was	determined	in	male	CD1	mice	(n=3	per	dose	route)	following	oral	(PO),	subcutaneous	(SC)	or	intraperitoneal	(IP)	dosing	at	a	target	dose	of	3	mg/kg	(5	mL/kg)	for	all	3	routes.	SGC0946	was	suspended	in	1%	methylcellulose	400	(aq)	or	dissolved	in	10%	(w/v)	Kleptose	HPB	for	the	PO	and	SC/IP	dose	groups	respectively.	The	systemic	exposure	of	SGC0946	post	insertion	of	 a	 surgically	 implanted	minipump	was	determined	 in	male	C57BLK	mice	(approximately	25	g,	n=3)	at	a	target	dose	of	6	mg/kg/h	(1	µL/h).	SGC0946	was	dissolved	in	10%	(w/v)	Kleptose	HPB	to	achieve	a	final	concentration	of	150	mg/mL.	Serial	blood	samples	(15	or	20	µL)	were	taken	via	the	tail	vein	over	the	time-course.	 Blood	 samples	 were	 diluted	 with	 an	 equal	 volume	 of	 water	 and	stored	at	ca.	–20oC	prior	to	analysis	by	LC-MS/MS.			
Blood	samples	were	analysed	for	SGC0946	using	an	analytical	method	based	on	protein	 precipitation	 and	 LC-MS/MS	 employing	 positive-ion	 electrospray	ionisation	using	an	Phenomenex	Kinetix	C18	LC	column	and	a	Sciex	API	4000	MS.	Pharmacokinetic	 data	 analysis	 was	 performed	 using	 non-compartmental	analysis	in	WinNonLin	Phoenix	v6.2	software.					
Syngeneic	murine	models	of	leukemia		Secondary	syngeneic	 transplantation	studies	were	performed	with	 intravenous	injection	 of	 2	×	 106	 cells	 obtained	 from	 bone	marrow	 or	 spleen	 into	 C57BL/6	male	mice,	all	mice	were	6–10weeks	old	at	time	of	sublethal	irradiation	at	a	dose	of	3Gy.	Treatment	with	vehicle,	 I-BET151,	SGC0946	or	both	began	at	day	8.	 	 I-BET	was	administered	via	intra-peritoneal	injection	at	10mg/kg/day	on	days	8,	9,	11,14	and	16.	SGC0946	was	administered	via	osmotic	mini-pumps	surgically	implanted,	and	were	filled	with	150mg/ml	to	deliver	a	dose	of	6mg/kg/h.	Pumps	were	 implanted	 at	 day	 8	 and	 left	 for	 the	 duration	 of	 the	 experiment.	 All	mice	were	kept	in	a	pathogen	free	animal	facility,	inspected	daily	and	sacrificed	upon	signs	of	distress	and	disease.	All	studies	were	conducted	in	accordance	with	the	GSK	Policy	on	the	Care,	Welfare	and	Treatment	of	Laboratory	Animals	and	were	reviewed	by	 the	 Institutional	Animal	Care	and	Use	Committee	either	at	GSK	or	were	conducted	under	institutional	animal	ethics	review	board	in	Australia	and	authorised	 by	 the	 Animal	 Experimentation	 Ethics	 Committee	 (AEEC),	 Peter	MacCallum	Cancer	Centre.	All	mice	were	randomised	prior	to	commencement	of	experiment.	 Animal	 technicians	 were	 blinded	 to	 experimental	 setup	 and	outcome.				
	
Inducible	shRNA	in	vivo	competition	assay		Secondary	MLL–AF9	cells	were	transduced	with	shScramble,	shDOT1L,	shBRD4	or	 both	 shDOT1l	 and	 shBRD4.	 Cells	 were	 sorted	 for	 BFP+,	 VENUS+	 or	BFP+/VENUS+.	 Doxocycline	 was	 then	 added	 to	 cells	 in	 vitro	 for	 48hrs	 and	DSRED+	 cells	 were	 sorted	 and	 immediately	 transplanted	 into	 NSG	mice.	 Mice	
were	 kept	 on	 DOX	 for	 the	 duration	 of	 the	 experiment.	 Peripheral	 blood	 was	taken	every	9	days.			
Combination	treatment	for	RNA-Seq	and	ChIP-Seq	MV4;11	 cells	 were	 seeded	 at	 1-2	 ×	 105	 per	 ml	 and	 treated	 with	 DMSO	 or	SGC0946	 (5µM)	 for	 72hrs,	 with	 I-BET	 (500nM)	 treatment	 commencing	 6hrs	prior	to	harvesting	alone	or	in	combination.		
RNA-Seq	RNA	for	RNA-Seq	was	prepared	using	the	Qiagen	RNeasy	kit.	RNA	concentration	was	quantified	with	 the	NanoDrop	spectrophotometer	(Thermo	Scientific).	The	integrity	 was	 assessed	 with	 the	 2100	 bioanalyzer	 using	 the	 RNA	 6000	 kit	(Agilent	 Technologies).	 Libraries	were	 prepared	 using	 the	 TruSeq	RNA	 library	preparation	 kit	 (Illumina).	 Libraries	were	 quantified	 by	 qPCR,	 normalised	 and	pooled	 to	 2nM	 before	 sequencing	with	 single-end	 50	 bp	 reads	 on	 an	 Illumina	HiSeq2500.	All	RNA-seq	experiments	were	done	in	duplicate.		
RNA-Seq	analysis	Reads	were	aligned	to	the	human	genome	(G1k	V37)	using	tophat2	and	bowtie2	and	 reads	 were	 assigned	 to	 genes	 using	 htseq-count42.	 Differential	 expression	was	 calculated	 using	 edgeR60.	 Genes	 with	 a	 false	 discovery	 rate	 corrected	 for	multiple	testing	using	the	method	of	Benjamini	and	Hochberg61	below	0.05	and	a	fold-change	 greater	 than	 1.5	 were	 considered	 significantly	 differentially	expressed.	Principal	 component	 analysis	 was	 performed	 on	 the	 variance	 stabilizing	transformed	 read	 counts62.	 Gene	 set	 testing	 using	 ROAST63	was	 performed	 on	voom-transformed	RNA-Seq	data.  
	
geneGO	MetaCore	analysis	
Diseases	 significantly	 associated	 with	 the	 genes	 co-regulated	 by	 I-BET	 and	SGC0946	were	identified	by	MetaCore	(Thomson	Reuters)	enrichment	analysis.			
Chromatin	Immunoprecipitation	(ChIP)	Cells	 were	 cross-linked	 with	 1%	 formaldehyde	 for	 15	 minutes	 at	 room	temperature	and	cross-linking	stopped	by	 the	addition	of	0.125M	glycine.	Cells	were	 then	 lysed	 in	 1%	 SDS,	 10mM	EDTA,	 50mM	Tris-HCl	 pH8.0	 and	 protease	inhibitors.	Lysates	were	sonicated	in	a	Covaris	ultrasonicator	to	achieve	a	mean	DNA	 fragment	 size	 of	 500bp.	 Immunoprecipitation	 (see	 antibodies)	 was	performed	for	a	minimum	of	12	hours	at	4°C	in	modified	RIPA	buffer	(1%	Triton	X,	 0.1%	 deoxycholate,	 90mM	 NaCl,	 10mM	 Tris-HCl	 pH8.0	 and	 protease	inhibitors).	 An	 equal	 volume	 of	 protein	 A	 and	 G	 magnetic	 beads	 (Life	Technologies)	were	used	to	bind	the	antibody	and	associated	chromatin.	Reverse	crosslinking	 of	 DNA	 was	 followed	 by	 DNA	 purification	 using	 QIAquick	 PCR	purification	kits	(Qiagen).	Immunoprecipitated	DNA	was	analysed	by	sequencing	(see	below)	or	qPCR	on	an	Applied	Biosystems	StepOnePlus	System	with	SYBR	green	 reagents.	 All	 ChIP-Seq	 experiments	 were	 performed	 once.	 Sequence	 of	primers	in	Supplementary	Notes.		
ChIP-Seq	analysis	Reads	 were	 aligned	 to	 the	 human	 genome	 (G1k	 V37)	 using	 bowtie264.	 Peak	calling	was	performed	using	MACS2	with	default	parameters65.	Genome	browser	images	of	ChIP-Seq	data	was	generated	by	converting	the	bam	files	from	bowtie2	to	 TDF	 files	 using	 igvtools	 and	 viewing	 in	 IGV66.	 ChIP-Seq	 coverage	 across	selected	genomic	regions	was	calculated	using	BEDtools67.			
Defining	subsets	of	I-BET	and	SGC0946	regulated	genes		ChIP	coverage	for	POL	II,	BRD4	and	H3K79me2	was	calculated	using	BEDTools67	in	all	expressed	ensemble	genes	including	1kb	promoter	region	and	normalized	for	read	depth	and	gene	length.	Genes	were	filtered	to	only	include	those	with	a	
minimum	 PolII	 ChIP	 reads	 per	 kilobase	 per	 million	 reads	 (RPKM)	 of	 of	 1	(corresponding	 to	 top	 50%	 of	 expressed	 genes).	 Genes	 with	 a	 ChIP-Seq	 fold	change	 comparing	 inhibitor-treated	 with	 DMSO-treated	 cells	 of	 at	 least	 –1.3	(corresponding	 to	 the	 top	 10%	 of	 most	 regulated	 genes)	 were	 considered	regulated.	Gene	set	enrichment	analysis	was	performed	with	GSEA68	or	ROAST63.		
Gene	coverage	profiles	Genes	 were	 divided	 into	 100	 segments	 between	 the	 TSS	 and	 TES,	 and	 5kb	upstream	and	downstream	of	the	gene	were	divided	into	20	intervals	of	250	bp	using	a	python	script.	ChIP-Seq	coverage	was	counted	 for	each	of	 the	 intervals	for	each	gene	using	BEDTools67.	The	median	number	of	reads	normalized	for	1	million	 reads	 in	 1kb	 region	 was	 calculated	 across	 all	 genes,	 and	 plotted	 for	different	sets	of	regulated	genes	using	ggplot269	in	the	R	statistical	programming	language70.		
Define	superenhancer	Peaks	identified	by	MACS2	in	BRD4	ChIP	in	DMSO	sample	were	intersected	with	K27ac	ChIP	to	 identify	 the	enhancers	with	both	BRD4	and	K27ac.	Peaks	within	12.5kb	 were	 merged,	 promoter	 regions	 within	 2.5kb	 of	 TSS	 were	 removed.	Enhancer	 regions	with	BRD4	coverage	 in	DMSO	sample	with	 reads	per	million	(RPM)	of	>3500	were	defined	as	superenhancers.	A	total	of	332	superenhancers	were	identified	in	MV4;11	cells.		
Enhancer	coverage	profiles	The	median	size	of	superenhancers	 is	approximately	25	 times	greater	 than	the	size	 of	 typical	 enhancers.	 Therefore	 superenhancers	 were	 divided	 into	 100	intervals,	typical	enhancers	were	divided	into	4	intervals	and	5kb	upstream	and	downstream	of	the	gene	were	divided	into	20	intervals	of	250	bp	using	a	python	script.	 Coverage	 of	 ChIP	 reads	 per	 kilobase	 per	 million	 reads	 (RPKM)	 was	
calculated	over	superenhancers	and	typical	enhancers	using	BEDTools67	and	the	median	was	plotted	for	different	treatments.		
ChIP-Seq	profile	plots	Profiles	 of	 ChIP-Seq	 reads	 in	 the	 5kb	 around	 the	 H4K5ac	 MACS	 peaks	 were	generated	with	Genomic	Tools71.		
Regulated	gene	numbers	Levels	 of	 H3K79me2,	 BRD4	 and	 H4K5ac	 were	 computed	 in	 ChIP-Seq	 peaks	within	 expressed	 genes	 using	 BEDTools	 and	 summed	 for	 each	 gene	 with	 R70.	Genes	 with	 a	 decrease	 of	 ChIP-Seq	 reads	 of	 1.3	 fold	 were	 considered	 to	 be	significant.			
4sU	labelling	of	newly	transcribed	RNA	4sU	 labelling	was	 performed	 to	 isolate	 newly	 transcribed	RNA72.	MV4;11	 cells	treated	with	DMSO,	500nM	I-BET	for	6	hours	and/or	5µM	SGC0946	for	3	days,	and	 labelled	 for	60	minutes	with	200µM	4sU	at	 the	end	of	 inhibitor	 treatment.	Total	RNA	was	isolated	from	with	TRIzol®	reagent.	The	RNA	was	denatured	by	heating	 to	 65°C	 for	 10	 minutes,	 then	 placed	 on	 ice.	 The	 labelled	 RNA	 was	biotinylated	 with	 2µg	 EZ-link	 HPDP-biotin	 (Thermo	 Fisher)	 per	 µg	 of	 RNA	 in	biotinylation	buffer	for	1.5	hours	at	RT.	The	biotinylated	RNA	was	extracted	with	an	 equal	 volume	 of	 chloroform	 twice,	 precipitated	 with	 ethanol,	 then	resuspended	 in	 water.	 The	 biotinylated	 RNA	 was	 purified	 with	 25	 µL	 of	Dynabeads	 M-280	 streptavidin	 (Thermo	 Fisher),	 washed	 four	 times	 with	washing	 buffer	 (5mM	 Tris-HCl	 pH7.5,	 0.5mM	 EDTA	 and	 1M	 NaCl).	 The	biotinylated	RNA	was	eluded	from	the	beads	with	100mM	DTT	and	purified	with	RNAeasy	MinElute	cleanup	(Qiagen)	kit.	RNA	concentration	was	quantified	with	the	NanoDrop	spectrophotometer	 (Thermo	Fisher).	The	 integrity	was	assessed	with	the	2100	bioanalyzer	using	the	RNA	6000	kit	(Agilent	Technologies).	cDNA	was	 synthesised	 from	 the	 recovered	 newly	 synthesised	 RNA	 with	 random	
hexamers.	Libraries	were	prepared	using	the	TruSeq	RNA	library	preparation	kit	(Illumina).	 Libraries	 were	 quantified	 by	 qPCR,	 normalized	 and	 pooled	 to	 2nM	before	 sequencing	with	 single-end	 50	 bp	 reads	 on	 an	 Illumina	 HiSeq2500.	 All	4sU	experiments	were	done	in	duplicate.		
	
Motif	analysis	Motif	 analysis	 was	 performed	 with	 CentriMo73	 on	 genomic	 regions	 with	 both	BRD4	and	H3K79me2	where	BRD4	binding	and	H4K5ac	levels	are	lost	following	SGC0946	treatment,	compared	with	regions	where	H4K5ac	levels	are	unaltered.		
Patient	material		Peripheral	 blood	 or	 bone	marrow	 containing	 >80%	 blasts	 was	 obtained	 from	patients	 following	 consent	 and	 under	 full	 ethical	 approval	 by	 the	 Peter	MacCallum	Cancer	Centre	human	research	ethics	committee.				 	
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Supplementary Figure 1 
Characterization of SGC0946 and the BRD4 or DOT1L containing protein complexes. 
 
 
(a) Co-immunoprecipitation (Co-IP) of endogenous BRD4, DOT1L, MLLT1, and LEO1 in MOLM-13 cells. IgG was used as a control. 
Co-IP was followed by western blot analysis with antibodies against BRD4. (b) Size exclusion chromatography followed by western blot 
analysis of BRD4 and DOT1L, in MV4;11 cells. (c) Dose response to SGC0946 treatment in MV4;11 cells by western blot analysis 
using H3K79me2 antibodies, total H3 was used as control. (d) Time course of SGC0946 treatment in MV4;11 cells followed by western 
blot analysis for H3K79me2. (e) Western blot analysis of various histone lysine methylations (H3K79me/2/3, H3K36me3, and 
H3K4me3) following SGC0946 treatment in MV4;11 cells. (f) MV4;11 cells were treated with vehicle (DMSO), SGC0946, I-BET or 
combination followed by western blot analysis with antibodies against H3K79me2 and total H3.  
 
 
 
 
Supplementary Figure 2 
Chemical Probes and Proliferation Assays.	
 
 
(a) Chemical structure of the DOT1L inhibitors used in this study. (b) Chemical structure of DOT1L inhibitor compounds used for bead 
immobilization. (c) Pull downs with DOT1L inhibitor compounds immobilized on beads at 2 different coupling densities (CD) in HL60 
nuclear extracts. 10µM FED1 (+) or DMSO (–) was used as soluble competitor. The eluates from the beads were analysed on Western 
blot using DOT1L antibodies. In vitro sub-therapeutic doses of (d) I-BET and (e) SGC0946 in MV4;11 cells. (f-h) Proliferation assay of 
the combination of low dose (LD, 100nM) I-BET plus low dose (LD, 1µM) SGC0946 in (f) SKM-1, (g) NB-4 (APML) and (h) HL-60 cells. 
Mean, error bars, s.d. (n = 2 cell culture replicates), representative graph from experiments done on 3 separate occasions.  
 
 
 
 
Supplementary Figure 3 
Phenotypic and Pharmacokinetic Analysis of Single and Combination Therapies. 
 
 
(a-b) Apoptotic response and cell cycle arrest in the combination treated cells. Annexin V staining of (a) MV4;11 and (b) K562 cells 
treated with either DMSO, SGC0946, I-BET, or combination. Mean, error bars, s.d. (n = 3 cell culture replicates), representative graph 
from experiments done on 3 separate occasions. (c-d) Cell cycle analysis by PI staining in (c) MV4;11 and (d) K562 cells treated with 
the inhibitors. These data show a cell cycle arrest in MV4;11 cells that is most prominent with combination therapy. Mean, error bars, 
s.d. (n = 3 cell culture replicates), representative graph from experiments done on 3 separate occasions. (e) Mouse pharmacokinetic 
studies comparing the blood concentration of SGC0946 administered via PO, SC or IP routes at 3 mg/kg (Samples taken post 2h below 
limit of quantification; 0.02 µM). Mean, error bars, s.d. (n = 3 mice per group). (f) Mouse pharmacokinetic study blood concentration-
time profile of SGC0946 administered via surgically implanted mini-pump targeting 6 mg/kg/h for 72 h. Required exposure for in vivo 
model achieved. Mean, error bars, s.d. (n = 3 mice per group).  (g) Western blot analysis of in vivo on-target activity of I-BET and 
SGC0946 on the bone marrows of three mice per group, using c-MYC, HSP60, H3K79me2 and total H3 antibodies.  
 
 
 
 
Supplementary Figure 4 
 
 
Inducible RNAi Knock-down of BRD4 and DOT1L. 
(a) Western blot and (b) qRT-PCR analysis of DOT1L expression in inducible RNAi samples. β-ACTIN was used as a loading control. 
(c) Western blot and (d) qRT-PCR analysis of BRD4 expression in inducible RNAi samples. HSP60 was used as a loading control. 
shDOT1L #7 and shBRD4 #498 were used in the competition assays (Figure 3c). (e) Schematic overview of the plasmids used. Flow 
plot examples showing cells transduced with single and combination inducible RNAi constructs expressing two different fluorophores. 
This strategy allowed for double knockdown within the same cell.  
 
 
 
 
 
Supplementary Figure 5 
Correlation of RNA-Seq and ChIP-Seq analysis of inhibitor treated cells. 
 
 
(a) GSEA using ROAST (Wu, D. et al. Bioinformatics 26, 2176–2182, 2010) of differentially expressed genes from RNA-Seq data of 
SGC0946 treated cells with previously published up- (red) and down-regulated (blue) genes from microarray analysis of MV4;11 cells 
treated with EPZ004777 (GSE29828). The shaded area in the centre of the plot shows genes ranked by log fold change in expression 
in SGC0946 compared with DMSO treated cells. Pink and blue shading represent significantly up- and down- regulated genes, 
respectively. (b) Heatmap of differential mRNA expression data from RNA-Seq of MV4;11 cells treated with I-BET, SGC0946, or 
combination in duplicate cell culture experiments. (c) geneGO analysis of the top ten diseases associated with the co-regulated genes. 
(d) Change in gene expression from RNA-Seq following BRD4 inhibition (I-BET), DOT1L inhibition (SGC0946) or a combination of 
BRD4 and DOT1L inhibition plotted against the changes in BRD4 binding and H3K79me2 levels in genes from ChIP-Seq. (e) 
Correlation between POL II and BRD4 binding or H3K79me2 levels at all genes in DMSO, I-BET and SGC0946 treated cells. 
 
 
 
 
Supplementary Figure 6 
ChIP-Seq analysis of superenhancer associated genes. 
 
 
(a) Enhancers ranked by increasing BRD4 ChIP-Seq signal in reads per million (RPM) mapped reads. (b) ChIP-Seq profile of BRD4, 
H3K27ac, H3K79me2 and POL II at a typical enhancer and superenhancer indicated in Supplementary Fig 6a, in red and blue 
respectively. (c) Median H3K79me2, BRD4 and POL II coverage in RPKM across the co-regulated genes following I-BET, SGC0946 or 
combination treatment. (d) Heatmap of the expression of genes in closest proximity to superenhancers with I-BET and SGC0946 
combination treatment. (e) qPCR analysis of H3K79me2 and BRD4 ChIP in MOLM-13 cells treated with SGC0946 using primers 
targeting CDK6, BCL2, MTHFD2 and Neg (negative control region). Mean, error bars, s.d. (n=3 technical replicates), representative 
graph from experiments done on 3 separate occasions 
 
 
 
 
Supplementary Figure 7 
SGC0946 Washout experiment. 
 
 
(a-b) Anti-H3K79me2 and anti-total H3 western blot. Samples are lysates from MV4;11 cells treated with DMSO or SGC0946 for 6, 8 
and 10h and (a) harvested at end of treatment or (b) after washout of SGC0946, then harvested 72 hours later. (c) Proliferation Assay. 
Cell counts after short term treatment of MV4;11 cells with SGC0946 for 6 hours followed by wash-out or continuous treatment with 
SGC0946. (d-e) qRT-PCR of BCL2 expression from MV4;11 cells treated with DMSO or SGC0946 for 6, 8 and 10h and (d) harvested 
at end of treatment or (e) after washout of SGC0946, then harvested 72 hours later. ChIP-qPCR analysis for (f) BRD4 and (g) 
H3K79me2. MV4;11 cells were treated with I-BET for 6 hours, SGC0946 for 8 hours, SGC0946 for 72 hours continuously or SGC0946 
for 8 hours followed by washout and assessed 72 hours later. Mean, error bars, s.d. (n=3 technical replicates), representative graph 
from experiments done on 3 separate occasions. (h), Median BRD4, H3K79me2 and POL II levels in RPKM across genes containing 
both BRD4 and H3K79me2 including 5kb upstream and downstream regions following short-term SGC0946 or SGC0946 washout 
treatment.  
 
 
 
 
Supplementary Figure 8 
Mechanism of BRD4 displacement by DOT1L inhibition. 
 
 
(a) Left, Flow chart hierarchy of the numbers of expressed genes with H3K79me2 and BRD4 peaks that change their expression and 
have decreased H379me2 levels after SGC0946 treatment. Right, scatterplot of the log-fold change in BRD4 and H3K79me2 after 
SGC0946 treatment in the 175 SGC0946 regulated genes. (b) qRT-PCR of genes identified by RNA-seq as being regulated by both 
BRD4 depletion and DOT1L inhibition. Mean, error bars, s.d. (n = 3 experiments done on 3 separate occasions). (c) Quantitative 
proteomic analysis of BRD3 and BRD4 within HL-60 nuclear extracts that are bound to various biotinylated histone H3K79 peptides. 
BRD3 and BRD4 captured by the histone peptides were differentially quantified by isobaric tagging, as previously performed (Dawson, 
M.A. et al. Nature 478, 529-33, 2011).  (d) ChIP-qPCR analysis of SGC0946 treated MOLM-13 cells using primers against CDK6, 
BCL2, MTHFD2 and Neg (Negative control region). Mean, error bars, s.d. (n=3 technical replicates), representative graph from 3 
experiments done on 3 separate occasions. (e) Scatterplot of the log-fold change in H3K79me2 and H4K5ac levels after DOT1L 
inhibition in the 175 SGC0946 regulated genes. (f) Log-fold change in the levels of H4K5ac in the subsets of I-BET regulated, 
SGC0946 regulated and co-regulated genes following SGC0946 treatment. The upper limit, center and lower limit of boxplots denote 
the upper quartile, median and lower quartile of the data, respectively. Whiskers extend to 1.5 × interquartile range above and below 
the upper and lower quartiles, respectively. (g) Western blot of CREB1. Lysate from MV4;11 cells transduced with the two independent 
shRNAs used in Figure 7. 	
